Brivaracetam (αR,4R) is a third-generation antiepileptic drug and anticonvulsant compound frequently used in combination with other antiepileptic compounds for the treatment of partial-onset seizures. It acts as a high-affinity ligand for synaptic vesicle protein 2A, reducing neurotransmitter release by binding to synaptic vesicle glycoprotein SV2A. Brivaracetam (αR,4R) is primarily metabolized into inactive metabolites through hydrolysis by amidase.